Discovery & Development Europe 2026
.png)
Estrel Congress Centre, Berlin, Germany
.png?width=450&height=220&name=Drug%20Discovery%20Europe%202026%20Updated%20(Light).png "Drug Discovery Europe 2026 Updated (Light)")
Programme
Day
AI-Driven Drug Discovery Platforms: Real Value, Real Limits
Panel Discussion• The AI platform landscape:
o Biology-first vs chemistry-driven vs lab-integrated approaches
o Where differentiation is real & where it is overstated
• Where AI is delivering value today
• How pharma is engaging with AI platforms in practice
• Scalability, integration, and long-term ROI
Digitalisation Including Generative AI – Case Study From Sanofi
Industry PresentationThe Real Impact Of AI On Drug Discovery Workflows
Panel Discussion• AI in:
o Drug design
o High throughput screening
o Hit finding
• Productivity gains, limits, and evolution of data/models
• Industry case studies on generative AI: what worked, why, and data sources
• Measuring success and identifying next steps for improvement
Start Up Presentation
Solution Provider PresentationAI Case Study
Industry PresentationSolution Provider Presentation
Solution Provider PresentationCandidate Optimisation With Physiologically-Based Pharmacokinetic Modelling
Industry PresentationLeveraging Affinity Screening For Hit Discovery
Industry PresentationAI-Guided Discovery of IAM1363: A Clinical-Stage, Next-Generation HER2 Type II Inhibitor with High Selectivity and Brain Penetrance
Industry PresentationIAM1363 is a potential best-in-class type II HER2 inhibitor with broad activity across HER2 mutants, >5,000-fold selectivity over EGFR, preferential tumor enrichment, and robust brain penetrance. Enabled by Iambic’s AI/ML and high-throughput platform, IAM1363 is currently being evaluated in a Phase 1b clinical trial.
Improving The Efficiency And Effectiveness By Implementing FAIR Guiding Principles For Pharmaceutical R&D Data
Industry PresentationDrug Discovery a:head: A Human Brain Organoid Screening Platform
Industry PresentationChemical Space Generation, Exploration & Visualisation
Industry PresentationFutures Of Small Molecule Discovery
Industry PresentationMultitarget Ligands for Multifactorial Diseases
Industry Presentation• Multifactorial diseases: cancer, neurological disease (Parkinson's, Alzheimer’s), microbial illness
• Multiple Targeting Drugs/Ligands (MTD) approach: Hybrid and Chimeric Drugs
• Azaheterocyclic derivatives for multifactorial diseases: design, synthesis, and biological activity of hybrid and chimeric derivatives
Smarter, Faster, Leaner: Digitalising Drug Product Development
Panel Discussion• Integrating PAT, digital twins & AI for continuous workflows
• Real-world impact: productivity gains and decision-making power
• Balancing innovation with regulatory compliance
Functional Genomics Approaches For Target Identification
Industry PresentationDrugging The Undruggables: TPD Approaches
Industry PresentationFunctional ADC Safety Profiling with iPSC-Derived Human Tissues
Solution Provider PresentationNext-Gen Payloads To Address ADC Resistance
Industry PresentationAI Case Study
Industry PresentationDesigning For Impact – Moving Beyond Inhibitors
KeynoteInnovative High-Throughput TSA & qPCR Platforms: New Opportunities In Drug Discovery
Industry PresentationHigh-throughput technologies provide a robust foundation for the discovery of novel lead structures. At Bayer, we have developed advanced platforms for high-throughput quantitative PCR (qPCR) and thermal shift assays (TSA). Case studies demonstrate how these technologies empowered successful hit identification. In addition, strategies for designing diverse and effective compound libraries are discussed, highlighting their critical role in successful screening campaigns.
High Throughput Biomarker Analysis
Industry PresentationDeveloping GAL3 Degraders For The Treatment Of Alzheimer’s Disease
Industry PresentationHit To Lead: How Are You Optimising Your Screening Strategy In 2026?
Panel Discussion• Evolving library design: full-deck vs focused screens
• Automation, DELs, and new assay formats
• Modalities and target classes: tailoring optimisation strategies
DEL Screening For Small Molecule Hit-To-Lead
Industry PresentationLessons from Building an AI-Ready Data Platform for Target Discovery
Industry PresentationFunctional genomics is exploding in drug discovery, making it hard to turn diverse, complex as-says into actionable insights. We addressed this at Novo Nordisk via an end-to-end data platform that guarantees compliance with a FAIR-by-design approach and unlocks immediate value through frictionless access, enabling confident decision-making from trusted data.
Solution Provider Presentation
Solution Provider PresentationAdvanced Screening Approaches
Industry PresentationGenerative Molecular Design – Advancing From Hits To Leads
Industry PresentationFocused Innovation Through Partnerships
Industry Presentation• Introduction to Lundbeck External Research & Innovation
• Recent examples of building partnerships with Lundbeck
Novel Hit Identification Strategies – Part 2
Industry PresentationModeling Ternary Complexes With Molecular Glues: Making Sense Of A Sticky Situation
Solution Provider PresentationFostering Cross-Sector Partnerships To Accelerate Drug Discovery
Roundtable Discussion• The future of partnering & what to prioritise
• Bringing together AI & data cross-functionally to drive drug discovery
Assays Around The Clock: Autonomous Robotics In Merck's Early Drug Discovery
Industry PresentationAutonomous Mobile Robots (AMRs) transform research by automating routine tasks and extending operational hours to nights and weekends. We are implementing our first AMR, integrating liquid handlers, incubators, and readers for fully automating any microtiter plate assay in our Lab of the Future. This pioneering solution will boost productivity and enhance research outcome
Preclinical Discovery for Novel ADCs
Industry PresentationIntegrating Multi-Omics Data To Understand Disease Mechanisms
Industry PresentationPreclinical Characterisation Of IPN60300, A First-In-Class Antibody-Drug Conjugate For Cancer Therapy
Industry PresentationUtilising Chemical Biology For Target Identification & Validation
Industry PresentationDEL Screening For Membrane Proteins
Industry PresentationTo Be Confirmed
Industry PresentationToward a foundational shift in AI-driven drug discovery: improving co-folding models with federated networks
Industry PresentationTarget 2035 – Accelerating Drug Discovery Through Partnerships
Industry PresentationData-Driven Drug Development
Industry PresentationThe Power Of Precision Radiation: Radiopharmaceuticals Transforming Targeted Oncology
Industry PresentationStrategies for Building a Forward-Looking, Value-Driven IP Portfolio
Roundtable Discussion• Tailoring IP portfolio architecture to therapeutic modality (from small molecules to complex biologics)
• The IP paradox in AI-driven drug discovery (inventorship, confidentiality, ownership)
The Future Of Protein Degradation: Beyond PROTACs & Molecular Glues
Panel Discussion• Expanding target scope
• Resistance mechanisms
• Clinical pipeline readiness
• New effectors for TPD
Generative AI For Real World Evidence
Industry PresentationMultimodal Screening Strategy For Discovery Of Novel Cereblon-Directing Molecular Glue Degraders And Neosubstrates
Industry PresentationCombining In Vitro & Mathematical Modelling To Predict Efficacy
Industry PresentationFrom Data Silos to Connected Knowledge: Accelerating Tech Transfers Through End‑to‑End Digitalisation
Industry PresentationConfounding Factors In Targeted Degradation Of Short-Lived Proteins
Industry PresentationOrganoids And Advanced Vitro Models: Improving Translation And Replacing The Use Of Animals
Industry PresentationLab Digitalisation & AI
Industry PresentationDiscovery of FKBP12-Based Competitive Molecular Glues
Industry PresentationHow Can We Leverage All Pre-Clinical Information To Inform The First In Human Trial?
Panel Discussion• PK, safety & biomarker data
• Clinical relevance of models
• Leveraging literature vs datasets
• Personalised medicine
• Regulatory considerations
Solution Provider Presentation
Solution Provider PresentationInnovative Functional Groups In Medicinal Chemistry To Accelerate Drug Discovery
Industry Presentation- Medicinal chemists are challenged to discover drugs for increasingly difficult targets, while reducing the time towards clinical candidate selection
- The more functional groups we can utilize in compound design, the higher our chances might be to succeed
- This presentation will highlight emerging functional groups in medicinal chemistry such as the N-trifluoromethyl group and demonstrate how they can be strategically applied to optimize for example potency, metabolic stability, and oral absorption
- Expect to leave this session with some inspiring new chemical features and data supporting their application to optimize the properties of compound series, generate IP, and accelerate drug discovery
Where Smart Capital Meets Science: Investing In The Next Wave Of Innovation & AI In Drug Discovery & Q&A Session
Panel Discussion• How investors evaluate emerging drug discovery technologies
o AI in drug discovery
• What drives funding decisions in a shifting biotech market
• Where capital is flowing next
• What drives founding decisions?
Solution Provider Presentation
Solution Provider PresentationFrom Discovery To Development: Making Partnerships Work
Industry PresentationChemical Probes As Drivers Of Phenotypic Screening And Discovery
Industry PresentationPractical Steps To Maximise AI Value In Drug Discovery - From Algorithm To Adoption
Solution Provider PresentationMaximising AI’s impact in drug discovery requires practical tools that empower scientists. It also necessitates a focus on the implementation of proven algorithms and organisational change. Using case study examples from our StarDrop and Cerella platforms we show how AI’s value can be demonstrated.
AI-Enhanced, Chemically Aware Workflows for Next-Generation Drug Discovery
Solution Provider PresentationCDD Vault is a secure, cloud-based platform that unifies chemistry and bioassay data across ELNs, registration systems, and analysis tools to drive reproducibility, collaboration, and AI/ML readiness.
FAIR Data Management In Labs Of The Future
Industry PresentationMulti-Omics Technologies For Novel Target Discovery
Industry PresentationNon Degrading Molecular Glues - Insights on Molecular Interactions for Inhibiting PPIs and GTPases
Industry Presentation- Non-Degrading molecular glues inhibit protein targets through formation of a ternary complex. In this talk, our development of macrocyclic molecular glues that recruits FKBP12 will be discussed in context of inhibiting PPIs and other target classes.
- The structural basis for inhibiting PPIs will be shown through X-Ray structural data of ternary complexes with disruption of the TRADD-TRAF2 PPI being detailed.
- Learning from structural based drug design using ternary crystal structures will be presented.
Advanced ADC Discovery Platforms
Industry PresentationMaking Automation Smarter At AstraZeneca
Industry PresentationAdvancing Industry & Academic Partnerships To Accelerate Drug Discovery
Panel DiscussionAdventures In Precision Medicine For Cancer: 25 Years After The Genome Sequence
Keynote• Oncology leads the way in genome-based medicine with estimates of at least 90 FDA approvals requiring biomarkers for optimal patient selection – almost half of all drugs authorized since 1998
• In discovery, ‘Drugging the Cancer Genome’ is being further enabled by technologies such as CRISPR, chemical probes, structure/fragment-based design, degraders (PROTACs and molecular glues), immune-targeting and AI/machine learning approaches
• In clinical development, use of the ‘Pharmacological Audit Trail’ framework is being enhanced by cheaper next generation sequencing, liquid biopsy, and innovative PK/PD modelling
From Proximity Induction To Degradation: Advancing Molecular Degraders At Merck Healthcare
Industry PresentationTargeted protein degradation presents a significant opportunity to tackle previously undruggable targets by utilizing the cell's proteasomal system to eliminate disease-causing proteins.
At Merck Healthcare KGaA, we have established specialized workstreams for bifunctional PROTACs and molecular glue degraders.
Examples of our hit identification from PPI, Del and hit characterization will be presented, highlighting our tailored assay suite to optimize these modalities in our drug discovery pipeline.
Pushing The Boundaries Of Target Discovery In 2026 & Beyond
Panel Discussion• How to make and de-risk decisions in drug discovery -target/indication prioritisation
• Accelerating discovery with AI-driven technologies
• Potential bottlenecks & future outlook
The Automation & AI Landscape In 2026
KeynoteCovalent Protein Kinase Inhibitors Targeting Cysteine And Beyond
Industry PresentationThe Toxicity Challenge: What’s Holding Back ADC Innovation?
Panel Discussion• Antibody engineering to improve toxicity
• Balancing potency vs tolerability in payload design
• Will novel formats improve the toxicity profile?
Human Translatable Cellular Models & Pre-Clinical Research
Industry PresentationAn Advanced ADC Platform & Design Principles
Industry PresentationRethinking The Pre-Clinical Modelling
Industry PresentationUtilising AI In Hit Identification
Industry PresentationBuilding A Truly Connected, Automated Discovery Lab
Panel Discussion• Bridging silos between devices, data platforms & teams
• Achieving interoperability: tech, teams, and standards
• Scaling automation from proof-of-concept to full lab adoption
Application of Affinity Prediction (ABFEP) to Fragment Screening – Retrospective Analysis and Future Application
Industry PresentationFive Requirements For AI‑Ready Pharma Data Curation
Solution Provider PresentationPharma executives and managers are racing to apply AI across drug discovery and development. But while the possibilities of AI advances can be very promising, many efforts falter before bringing home dependable, real‑world performance. This session outlines five essential elements for preparing your data, systems, and scientific workflows for AI success. You’ll learn why strong data governance, complete metadata, interoperable platforms, resilient model‑management processes, and scientific validation are critical for trustworthy, reproducible results. By aligning these elements early, you'll enable faster decisions, fewer surprises, and you'll develop AI tools that deliver more consistent value across the drug development lifecycle.
To Be Confirmed
Industry PresentationTBC
Solution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationAdvanced Medicinal Chemistry Techniques
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationTo Be Confirmed
Industry PresentationTBC
Solution Provider Presentation
Solution Provider PresentationLeading The Future: Women Driving Innovation In Drug Discovery & Development
Panel Discussion• Career journeys and lessons from senior women in pharma, biotech, and academia
• Navigating leadership challenges, mentoring, and fostering inclusive R&D teams
• Breaking silos: cross-functional collaboration to accelerate drug development
• Inspiring the next generation of women scientists and leaders
Enabling Challenging Targets: Development of AS-MS and Integration with Other Screening Technologies
Industry PresentationTBC
From Device To Local Dose At The Site Of Action: In Silico Trials For Inhaled Drug Development
Innovation Presentation• Drug deposition determines efficacy, yet the local dose at the site of action is rarely quantified during development • Twinhale simulates aerosol transport and local deposition in patient-specific lungs using CT-derived anatomy, breathing patterns, and in vitro aerosol data • The platform enables virtual cohort studies and variability analysis prior to clinical trials • Applications include device selection, dose translation to humans, and supporting bioequivalence or bridging strategies using modelintegrated evidence
Start Up Presentation
Innovation PresentationSolution Provider Presentation
Solution Provider PresentationPUREfrex® – The Re-Built Protein Factory
Solution Provider PresentationPUREfrex® is a rebuilt, cell-free protein expression system that redefines how proteins are produced and explored. Its modular architecture offers researchers precise control at the molecular level, making it exceptionally adaptable to a wide range of applications—from expressing challenging biologics to enabling high-throughput workflows. Whether you're working on therapeutic proteins, novel modalities, or synthetic biology prototypes, PUREfrex® provides a flexible and efficient foundation. When paired with AI/ML platforms, it becomes a powerful accelerator for innovation in protein engineering and discovery.
To Be Confirmed
Industry PresentationSolution Provider Presentation
Solution Provider PresentationWhy DEL? Barriers And Opportunities In Data-Driven Drug Discovery
Solution Provider PresentationExploiting modern data science techniques in drug discovery requires platforms that generate data of sufficient scope and quality. DNA-encoded library (DEL) screening is one such data-intensive platform. In this talk, the hallmarks of effective utilization of DEL will be examined, and successful cases studies shared.
Targeted Glues™, A New Class of Degraders That Recruit Novel E3 Ligases
Industry Presentation• Traditional targeted protein degradation approaches require high affinity binders to E3 ligases to generate PROTACs or molecular glues, which limits the scope of E3 ligases regularly used
• At Amphista we take a target first approach to degrader discovery, generating glue like molecules based on target binding ligands. This has enabled generation of Targeted Glue™ degraders against high value targets using three non CRBN/VHL ligases
• Learnings from our pipeline programs will be presented, demonstrating the advantages of Targeted Glues and our approach to compound optimization
From Islands to Ecosystems: Interoperability as the Foundation for Lab-in-the-Loop IT Architectures
Industry PresentationWhat does it take to move from automated workflows to autonomous R&D cycles?
This talk explores the architectural requirements for lab-in-the-loop concepts and shows how interoperability standards like SiLA enable seamless integration, scalability, and real-time interaction between AI models and laboratory infrastructures.
Designing A Unified European Biotech Ecosystem
Industry PresentationTo Be Confirmed
Industry PresentationStart Up Presentation
Innovation PresentationStart Up Presentation
Innovation PresentationStart Up Presentation
Innovation PresentationStart Up Presentation
Innovation PresentationPeripherical-Only, Non-Addicted Nanotech Based Drug Delivery – Building Blocks For A Strategy To Prevent Opioid Addiction
Innovation PresentationSolution Provider Presentation
Solution Provider PresentationStart Up Presentation
Solution Provider PresentationThe Rise And Fall Of SARM1 Base-Exchange Inhibitors
Industry PresentationIntegrating iPSC-Based Disease Modelling Into The DZNE Translational Pipeline
Industry PresentationModulating Sleep As An Entry Point To Treating Neurodegenerative Disorders
Industry PresentationIs The Neurometabolic Approach The Missing Link In Neurodegenerative Disease Treatment?
Industry PresentationMoving Toward A Definition For Neuroinflammation
Panel Discussion• Exploring what we really mean by neuroinflammation
• Highlighting key cellular and immune features involved in brain inflammation
• Considering how clearer definitions could guide future research and treatment
NIDB-3101: A Third Generation Anti-Tau Biparatopic Antibody Designed For Enhanced Therapeutic Efficacy In AD
Industry Presentation• NIDB-3101 binds two distinct Tau epitopes and has Fc mutations for enhanced half-life
• NIDB-3101 binds a larger variety of Tau entities from AD brain tissue than benchmark Abs and robustly inhibits AD brain-derived seeds induced intracellular Tau aggregation
• The combination of sub-nanomolar affinity and cellular activity together with enhanced half-life leads to a modelled lower human efficacious dose than benchmark
Closed-Door Panel Discussion: Partnerships, Platforms Or Acquisitions: What Is The Winning Model For Brain Health Innovation?
Panel Discussion• Pharma-biotech-academia collaboration models that actually work
• When to partner vs acquire vs build internally
• Data-sharing in a competitive landscape
• Public-private partnerships in Europe: success stories & failures
• Regional differences – US vs EU
o Scaling in Europe
Neuroscience At Servier – Case Studies From The Clinic
Industry PresentationUsing Experimental Medicine To Accelerate Target Selection For Parkinson’s Disease Psychosis
Industry Presentation• Theoretical position for intracellular kinase modulation
• Experimental modelling to validate target/drug probe
• Initial data in patients
Advancing Paediatric Genetic Medicines
Industry PresentationSolution Provider Presentation
Solution Provider PresentationA Novel Platform For Identifying New Therapeutics
Industry PresentationSolution Provider Presentation
Solution Provider PresentationIs Neuroscience The Next Oncology? Industry Trends In Therapeutic Focus
Panel Discussion• Key drivers behind renewed pharma and biotech interest (e.g., Alzheimer’s approvals, novel mechanisms, better biomarkers)
• Understanding the underlying biology of neurological indications
• How can we get better in our understanding the full picture of the diseases?
Neuroimmune Targeting: From iPSC Models To AI-Driven Insights
Panel DiscussionThe UK Landmark Project: A Large-Scale, Multi-Pharma, Public-Private Partnership For Drug Target And Biomarker Discovery In Parkinson’s Disease
Industry PresentationLeveraging iPSC Models To Understand Neuroinflammatory Targets
Industry PresentationUsing iPSC-derived microglia models, this presentation explores neuroinflammatory mechanisms in Alzheimer’s disease. We examine how risk SNPs, including APOE-dependent and independent variants, alter microglial responses, and how female-specific X chromosome aging and escape genes shape disease phenotypes, neuronal survival, and sporadic Alzheimer’s disease risk in females.
A Human Stem Cell Derived Micorglia Single Cell Atlas - State Transitions In Response To Challenge
Industry PresentationGeneration of single cell RNA seq altas of iPSC microglia from 20 prodromal AD donors
Microglial states and their transition in response to different challenges
Molecular pathways induced by challenge
Solution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationBack To The Future – New Tools And Strategies For Modeling Neurodegenerative And Neuropathological Processes
Solution Provider PresentationSolution Provider Presentation
Solution Provider Presentation
Announcement of Young Scientist Poster Presentation Awards by ELRIG & Start of Wine Tasting Activities
Morning Break & Refreshments
Morning Break & Refreshments
Solution Provider Presentation
Solution Provider PresentationA Novel OncoLytic Peptide platform - Immunogenic Cell Death initiation for Immune Cell Recruitment
Industry Presentation• Novel Oncolytic Peptide therapies for hard to treat cancers
• Membrane-Lytic Peptides and immunogenic cell death
• Reprogramming the local tumour microenvironment for systemic response
Unlocking Non Traditional Delivery Routes For Small Molecule Therapeutics
Industry Presentation• Why intranasal delivery is compelling for small molecules
• Formulation and device considerations unique to intranasal products
• Development, safety, and translational challenges
Small Molecule Formulations & Dosage Form With Patient Friendly Delivery Considerations
Industry PresentationOligonucleotide Delivery & Utilising sRNA Delivery Methods In Alternative Modalities
Keynote
Lunch Break
Afternoon Break & Refreshments
End of Event
Lunch Break
Including Scheduled Demos in the AI & Digitisation Zone by AI Platform Companies
Solution Provider Presentation
Solution Provider PresentationSeparation Of PS Diastereomers In GalNAc-Conjugated siRNA By IP‑RP, AEX & HILIC
Industry PresentationRegulatory Hurdles For Biologics Delivery & Formulation
Industry PresentationOpportunities And Challenges In Developing And Manufacturing Radiopharmaceuticals
Industry Presentation• Expanding theranostic applications
• Complex manufacturing, isotope supply constraints, and short half-life logistics
• Regulatory hurdles, GMP compliance, and specialised infrastructure requirements
Oral Dosage Form Improvement
Industry PresentationNext-Generation Drug Delivery Devices: Balancing Patient Experience, Safety, And Performance
Panel Discussion• Design innovation & regulatory considerations
• Human factors & adherence
Challenges And Unities For The Delivery Of Biopharmaceuticals
Panel Discussion• Recent technological advancements & platforms
• Predicting future successes
Overcoming Scientific And Technological Challenges Of Formulating Oral GLP-1 Therapies
Panel DiscussionExploring Alternative Routes Of Administration For Biologics Beyond IV
Roundtable DiscussionLiposomal Formulation Development: Safety And Efficacy Assessment
Industry PresentationCharacterising Chemical And Physical Properties
Industry PresentationpH Gradient Driven Loading of Anticancer drug into Niosomes with Bromocresol Green as a Visual Indicator
Industry Presentation- Studying the effect of different co-surfactants on stabilising the niosomal membrane.
- Investigating the influence of niosomes' compositions on formation of a pH gradient.
- Visualisation of pH gradients via pH indicator bromocresol green (BCG) as a novel encapsulated model molecule to visually investigate the ability of niosomes to entrap drugs through active loading.
- Application of the most optimised BCG niosomal formulation to encapsulate a therapeutic anticancer drug molecule via pH gradient active loading.
NAMS Approaches For Ethical Drug Development
Roundtable DiscussionTackling Challenges With mRNA Delivery
Panel Discussion• Innovative mRNA formulations and delivery approaches
• Improving selectivity and efficiency of delivery
• Utilising data driven approaches to cover come delivery challenges
siRNA Therapies Utilising Lipid Nanoparticles
Industry PresentationOvercoming Challenges Of Clinical Formulations For PROTAC
Industry PresentationCell & Gene Delivery Platforms & Technologies
Industry PresentationFormulating Next-Gen Biotherapeutics: Strategies To Enhance Stability, Quality, And Scalability
Panel Discussion• Stabilising complex modalities
• Evaluating non-traditional formulation strategies — including lyophilisation, co-formulation, microencapsulation, or amorphous systems
Ophthalmology Formulation For Biologics Delivery
Industry PresentationFrom Molecule To Mouth: The Innovation Behind Oral GLP‑1
Industry Presentation• Key scientific breakthroughs enabling oral GLP‑1 (enhancers, formulation, devices)
• Translational challenges and clinical proof-of-concept
• Next-generation strategies for improving efficacy and scalability
Solution Provider Presentation
Solution Provider PresentationEx-Vivo Platform Development For Topical Treatments
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationFrom Expert Silos To Enterprise Capabilities: Democratising Modeling & Simulation In Pharmaceutical Development
Industry Presentation• Democratisation of M&S: From expert tools to self-service simulation app
• Empowering formulation scientists with validated first-principle models
• Enabling virtual experiments before lab work to accelerate development
mRNA Design With Lipid Nanoparticles & AI Assistance
Industry PresentationRegulatory Landscape Of Smart Devices
Industry PresentationLarge Molecules Formulation For Inhaled Therapies
Industry PresentationThe Future Of Biologics Delivery: High-Concentration Subcutaneous Administration
Panel Discussion• Latest scientific and engineering advances enabling high-dose, low-viscosity SC delivery of monoclonal antibodies and other biologics
• Aligning delivery platform decisions with long-term competitiveness, patient access, and global commercialisation strategies
Peptide Delivery Reimagined: Navigating Challenges And Seizing Opportunities For Oral Delivery
Industry Presentation• Challenges of GLP-1 formulations ensuring stability, permeability, solubility enhancement and overall effectiveness of the final product
• Key formulation strategy to enhance oral administration of peptides
Innovations In Biologics Formulation And Processes
Industry PresentationPrediction Of Longterm Stability Of Monoclonal Antibodies Using Innovative Biophysical And Data Science Tools
Industry Presentation• Advanced biophysical characterisation to understand degradation pathways and stability risks
• Integration of data science and predictive modelling to forecast long-term stability
• Accelerating developability assessment and formulation decision-making through in-silico insights
The Nitrosamines Formulation Hurdle
Industry Presentation• Crystal defects have been shown as the primary cause of nitrosamine formation in ranitidine hydrochloride
• Recrystallisation of ranitidine hydrochloride can essentially stop the formation of nitrosamines on storage by eliminating crystal defects
• This technology can be used in conjunction with traditional nitrosamine-reducing approaches to further mitigate nitrosamine formation for all crystalline drugs
Brain Health: A Call For Global Action & Unity
KeynoteFrom Amorphous To Manufacturable: Precipitation And Continuous Processing
Industry Presentation• Direct precipitation was selected to allow production of manageable Drug Substance (DS) amorphous
• Continuous DS processing implemented although scale-up and materials challenges resulted in the need for a mitigation plan
• Aiming to strengthened DS–Drug Product interface by generating consistent physical attributes
Strategies For High-Concentration Subcutaneous Antibody Therapeutics
Industry Presentation• Challenges and opportunities in developing high-dose antibody formulations suitable for subcutaneous administration
• Overview of innovative formulation and delivery approaches for high-concentration biologics
• Key considerations related to manufacturability, scalability, and regulatory expectations for next-generation antibody therapeutics
Formulation Development For Established & Emerging Modalities
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationJekyll, Hyde, and the Molecule in Between: A Formulation Mystery Solved Early
Solution Provider PresentationDrug development can feel like detective work – especially when a molecule changes character unexpectedly. Through the lens of Dr Jekyll and Mr Hyde, this session uncovers the clues hidden in solubility, stability, and solid state behaviour that only strong preformulation practice can reveal. Come for the literary twist; stay for the science that saves programs time, cost, and complexity.
Using Dissolution-Permeation Assays to Understand Various Aspects of Oral Drug Absorption
Solution Provider PresentationAchieving effective absorption and therapeutic efficacy is critical for the success of oral small molecule drugs. To optimize performance, a deep understanding of key biopharmaceutic properties—such as solubility, dissolution, and membrane permeability—is essential, as these parameters directly impact bioavailability and clinical outcomes.
This session will present innovative in-vitro methodologies designed to enhance developability assessments of small molecules and emphasis will be placed on dynamic dissolution and absorption models, which, when integrated with mechanistic modeling, provide valuable insights into rate-limiting steps in oral absorption. Selected case studies will illustrate the impact of food on oral drug absorption, the possible benefits of using nanoparticle formulations, and the impact of dose level on altering the mechanism for oral absorption when comparing pre-clinical to clinical outcome.
Improvement Of Oral Bioavailability Of Acylated Peptides
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationParticle Engineering To Drive Sustainability
Industry Presentation30-Minute Plenary Panel Discussion: The Landscape Of Drug Formulation & Delivery: What Will Actually Work?
Panel Discussion• Matching molecule to modality: ADCs, monoclonal antibodies, and nano-enabled delivery
• Route of administration as a differentiator: IV, SC, oral, and beyond
• Which delivery technologies are truly disruptive
o AI
o Automation
o Digital technologies & tools
No sessions found matching your filters.